When and how do i use neoadjuvant chemotherapy for breast cancer?

Current Treatment Options in Oncology

Volumn 15, Issue 1, 2014, Pages 86-98

  Rapoport, Bernardo L ^a   Demetriou, Georgia S ^b   Moodley, Shun D ^c   Benn, Carol A ^c  

^a Medical Oncology Center of Rosebank   (South Africa)

^b University of the Witwatersrand   (South Africa)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Anthracycline; Inoperable inflammatory breast cancer; Neoadjuvant chemotherapy; Pathological complete response; Taxane; Trastuzumab; Triple negative breast cancer

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; CAPECITABINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; LAPATINIB; LETROZOLE; METHOTREXATE; NAVELBINE; PACLITAXEL; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; DRUG CHOICE; DRUG TOLERABILITY; EVENT FREE SURVIVAL; FEMALE; HUMAN; INFLAMMATORY BREAST CANCER; MONOTHERAPY; OVERALL SURVIVAL; TREATMENT DURATION;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; INFLAMMATORY BREAST NEOPLASMS; NEOADJUVANT THERAPY; NEOPLASM STAGING; RECEPTOR, ERBB-2; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84894651626     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-013-0266-0     Document Type: Article

References (48)

1. Frei III E. Clinical cancer research: an embattled species. Cancer. 1982;50:1979-92.
2. Singletary SE, Allred C, Ashley P, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol. 2002;20:3628-36.
3. Hortobagyi GN, Ames FC, Buzdar AU, et al. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer. 1988;62:2507-16.
4. van der Hage J, van de Velde C, Julien J-P, et al. Preoperative chemotherapy in primary breast cancer: results from the European Organization for Research and Treatment of Cancer Trial 10902. J Clin Oncol. 2001;19:4224-37.
5. Fisher E, Wang JQ, Bryant J, et al. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer. 2002;95:681-95.
6. Chollet P, Amat S, Cure H, et al. Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Br J Cancer. 2002;86:1041-6.
7. Conte PF, Alama A, Bertelli G, et al. Chemotherapy with estrogenic recruitment and surgery in locally advanced breast cancer: clinical and cytokinetic results. Int J Cancer. 1987;40:490-4.
8. Herrada J, Iyer RB, Atkinson EN, et al. Relative value of physical examination, mammography, and breast sonography in evaluating the size of the primary tumor and regional lymph node metastases in women receiving neoadjuvant chemotherapy for locally advanced breast carcinoma. Clin Cancer Res. 1997;3:1565-9.
9. DeLena M, Varini M, Zucali R, et al. Multimodal treatment for locally advanced breast cancer: results of chemotherapy-radiotherapy versus chemotherapy-surgery. Cancer Clin Trials. 1981;4:229-36.
10. Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. Clin Oncol. 1997;15:2483-93.
11. Wolmark N, Wang J, Mamounas E, et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001;30:96-102.
12. Swain SM, Sorace RA, Bagley CS, et al. Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer. Cancer Res. 1987;47:3889-94.
13. Mauriac L, Durand M, Avril A, et al. Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single center. Ann Oncol. 1991;2:347-54.
14. Scholl SM, Fourquet A, Asselain B, et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumors considered too large for breast-conserving surgery: preliminary results of a randomized trial. Eur J Cancer. 1994;30A:645-52.
15. Valagussa P, Zambetti M, Bignami P, et al. T3b-T4 breast cancer: factors affecting results in combined modality treatments. Clin Exp Metastasis. 1983;1:191-202.
16. Rubens RD, Sexton S, Tong D, et al. Combined chemotherapy and radiotherapy for locally advanced breast cancer. Eur J Cancer. 1980;16:351-6.
17. Monzeglio C. Chemotherapy with estrogenic recruitment and surgery in locally advanced breast cancer: clinical and cytokinetic results. Int J Cancer. 1987;40:490-4.
18. Jacquillat C, Baillet F, Weil M, et al. Results of a conservative treatment combining induction (neoadjuvant) and consolidation chemotherapy, hormonotherapy, and external and interstitial irradiation in 98 patients with locally advanced breast cancer (IIIA-IIIB). Cancer. 1988;61:1977-82.
19. Pawlicki M, Skolyszewski J, Brandys A. Results of combined treatment of patients with locally advanced breast cancer. Tumori. 1983;69:249-53.
20. Balawajder I, Antich PP, Boland J. An analysis of the role of radiotherapy alone and in combination with chemotherapy and surgery in the management of advanced breast carcinoma. Cancer. 1983;51:574-80.
21. Smith IC, Heys SD, Hutcheon AW, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol. 2002;20:1456-66.
22. Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008;26:778-85. Classic landmark studies in the field of neoadjuvant chemotherapy in breast cancer.
23. Heys SD, Hutcheon AW, Sarkar TK, et al. Aberdeen Breast Group. Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast Cancer. 2002;3:S69-74.
24. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol. 2001;19:3808-16.
25. Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. 2010;375:377-84. The addition of neoadjuvant transtuzumab significantly improved the percentage of pCR in HER-2 overexpressing patients.
26. Ueno NT, Buzdar AU, Singletary SE, et al. Combined- modality treatment of inflammatory breast carcinoma: twenty years of experience at MD Anderson Cancer Centre. Cancer Chemother Pharmacol. 1997;40:321-9.
27. Baldini E, Gardin G, Evangelista G, et al. Long-term results of combined-modality therapy for inflammatory breast carcinoma. Clin Breast Cancer. 2004;5:358-63.
28. Christofanilli M, Gonzalez-Angulo AM, Buzdar AU, et al. Paclitaxel improves the prognosis in estrogen receptor-negative inflammatory breast cancer: the M.D. Anderson Cancer Centre experience. Clin Breast Cancer. 2004;4:415-9.
29. Thomas E, Holmes FA, Smith TL, et al. The use of alternate, non-crossresistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial. J Clin Oncol. 2004;22:2294-302.
30. von Minckwitz G, Kümmel S, Vogel P, et al. Neoadjuvant vinorelbine capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst. 2008;100:542-51.
31. Wesolowski R, Budd GT. Neoadjuvant therapy for breast cancer: assessing treatment progress and managing poor responders. Curr Oncol Repo. 2009;11:37-44.
32. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1988;16:2672-85.
33. Bear HD, Anderson S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: national surgical adjuvant breast and bowel project protocol B-27. J Clin Oncol. 2006;24:2019-27.
34. Mauri D, Pavlidis N, Ionnidis JP, et al. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. 2005;97:188-94.
35. von Minckwitz G, Untch M, Blohmer J-U, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30:1796-804. This paper elucidates the various pCR rates amongst biological breast cancer subtypes.
36. Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005;23:3676-85.
37. Untch M, Rezai M, Loibl S, et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the Geparquattro study. J Clin Oncol. 2010;28:2024-31. The addition of neoadjuvant transtuzumab significantly improved the percentage of pCR in Her-2 overexpressing patients.
38. Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2012;379:633-40. The addition of neoadjuvant lapatinib to trastuzumab and chemotherapy significantly improved the percentage of pCR in Her-2 overexpressing patients.
39. Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet. 2012;13:25-32. The addition of neoadjuvant pertuzumab to trastuzumab and chemotherapy significantly improved the percentage of pCR in Her-2 overexpressing patients.
40. Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24:2278-84. The addition of neoadjuvant pertuzumab to transtuzumab and chemotherapy significantly improved the percentage of pCR in Her-2 overexpressing patients.
41. Kim MM, Allen P, Gonzalez-Angulo AM, et al. Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer. Ann Oncol. 2013;24:1999-2004.
42. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26:1275-81.
43. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13:2329-34.
44. Hugh J, Hanson J, Cheang MCU, et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol. 2009;27:1168-76.
45. Loesch DM, Greco F, O'Shaughnessy J, et al. A randomized, multicenter phase III trial comparing doxorubicin + cyclophosphamide followed by paclitaxel or doxorubicin + paclitaxel followed by weekly paclitaxel as adjuvant therapy for high-risk breast cancer. J Clin Oncol. (Meeting Abstracts) 25: 18S (June 20 Supplement), 2007:517.
46. von Minckwitz G, Eidtmann H, Rezai M, et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med. 2012;366:299-309. To date, the addition of VGEF blockade has not been shown to improve outcomes in the neoadjuvant setting.
47. Bear HD, Tang G, Rastogi P, et al. The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40. J Clin Oncol. 2011;29(Suppl):1005.
48. Lee CH, Dershaw DD, Kopans D, et al. Breast cancer screening with imaging: recommendations from the Society of Breast Imaging and the ACR on the use of mammography, breast MRI, breast ultrasound, and other technologies for the detection of clinically occult breast cancer. J Am Coll Radiol. 2010;7:18-27.